Leishmaniasis is a parasitic disease that ranges in severity from skin lesions to fatality. Since long-lasting protection is induced upon recovery from cutaneous leishmaniasis, development of an effective vaccine is promising. However, there is no vaccine for use in humans yet. It seems limited efficacy in leishmaniasis vaccines is due to lack of an appropriate adjuvant or delivery system. Hence, the use of particulate adjuvants such as liposomes for effective delivery to the antigen presenting cells (APCs) is a valuable strategy to enhance leishmaniasis vaccine efficacy. The extraordinary versatility of liposomes because of their unique amphiphilic and biphasic nature allows for using antigens or immunostimulators within the core, on the surface or within the bilayer, and modulates both the magnitude and the T-helper bias of the immune response. In this review article, we attempt to summarize the role of liposomal adjuvants in the development of Leishmania vaccines and describe the main physicochemical properties of liposomes like phospholipid composition, surface charge, and particle size during formulation design. We also suggest potentially useful formulation strategies in order for future experiments to have a chance to succeed as liposomal vaccines against leishmaniasis.
CroftSLSundarSFairlambAH. Drug resistance in leishmaniasis. Clin Microbiol Rev2006; 19: 111–126.
2.
KhatamiAFiroozAGorouhiFet al. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol2007; 57: 335. e1–e29.
3.
SacksDNoben-TrauthN. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol2002; 2: 845–858.
4.
ScottPNovaisFO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol2016; 16: 581–592.
5.
KhamesipourARafatiSDavoudiNet al. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res2006; 123: 423–438.
6.
ModabberF. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents2010; 36: S58–S61.
7.
CostaCHNPetersNCMaruyamaSRet al. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl Trop Dis2011; 5: e943.
8.
NoazinSKhamesipourAMoultonLHet al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—a meta-analysis. Vaccine2009; 27: 4747–4753.
9.
NoazinSModabberFKhamesipourAet al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine2008; 26: 6759–6767.
10.
ColerRNReedSG. Second-generation vaccines against leishmaniasis. Trends Parasitol2005; 21: 244–249.
11.
GillespiePMBeaumierCMStrychUet al. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine2016; 34: 2992–2995.
12.
OkworIUzonnaJ. Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum Vaccin2009; 5: 291–301.
13.
AndradeBdBDe OliveiraCBrodskynCIet al. Role of sand fly saliva in human and experimental leishmaniasis: current insights. Scand J Immunol2007; 66: 122–127.
14.
KhamesipourADowlatiYAsilianAet al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine2005; 23: 3642–3648.
MutisoJMMachariaJCGicheruMM. A review of adjuvants for Leishmania vaccine candidates. J Biomed Res2010; 24: 16–25.
17.
NordlyPMadsenHBNielsenHMet al. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin Drug Deliv2009; 6: 657–672.
18.
BhowmickSAliN. Recent developments in leishmaniasis vaccine delivery systems. Expert Opin Drug Deliv2008; 5: 789–803.
19.
HigginsSCMillsKH. TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants. Curr Infect Dis Rep2010; 12: 4–12.
20.
Campos-NetoA. Anti-leishmania vaccine. In: FarrellJP (eds) Leishmania: world class parasites. Vol. 4. Boston, MA: Springer, 2002, pp.169–190.
21.
VajdyMSrivastavaIPoloJet al. Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines. Immunol Cell Biol2004; 82: 617–627.
22.
GurunathanSPrussinCSacksDLet al. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med1998; 4: 1409–1415.
23.
Palatnik-de-SousaCB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine2008; 26: 1709–1724.
24.
ReedSGBertholetSColerRNet al. New horizons in adjuvants for vaccine development. Trends Immunol2009; 30: 23–32.
25.
BadieeASharghVHKhamesipourAet al. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine2013; 31: 735–749.
26.
GarçonNChomezPVan MechelenM. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines2007; 6: 723–739.
27.
KshirsagarNPandyaSKirodianBet al. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med2005; 51(Suppl. 1): S5–S15.
28.
WatsonDSEndsleyANHuangL. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine2012; 30: 2256–2272.
29.
SharmaASharmaUS. Liposomes in drug delivery: progress and limitations. Int J Pharm1997; 154: 123–140.
30.
RaoMAlvingCR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv Drug Deliv Rev2000; 41: 171–188.
31.
BadieeAJaafariMRKhamesipourAet al. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf B Biointerfaces2009; 74: 37–44.
32.
MazumdarTAnamKAliN. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J Parasitol2005; 91: 269–274.
33.
BadieeAJaafariMRKhamesipourA. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol2007; 115: 127–134.
34.
JaafariMRGhafarianAFarrokh-GisourAet al. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine2006; 24: 5708–5717.
35.
KahlLScottCLelchukRet al. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol1989; 142: 4441–4449.
36.
ColhoneMCSilva-JardimIStabeliRGet al. Nanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes. J Microencapsul2015; 32: 143–150.
37.
SharmaSKDubeANadeemAet al. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine2006; 24: 1800–1810.
38.
SamieiATamadonAMSamaniSMet al. Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccines. Iran J Basic Med Sci2014; 17: 772–778.
39.
HojatizadeMBadieeAKhamesipourAet al. DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice. Nanomedicine2017; 4: 71–82.
40.
AfrinFAliN. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun1997; 65: 2371–2377.
41.
AfrinFAnamKAliN. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J Parasitol2000; 86: 730–735.
42.
BhowmickSRavindranRAliN. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine2007; 25: 6544–6556.
43.
BhowmickSRavindranRAliN. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun2008; 76: 1003–1015.
44.
BadieeAJaafariMRKhamesipourAet al. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Exp Parasitol2009; 121: 362–369.
45.
BhowmickSMazumdarTSinhaRet al. Comparison of liposome based antigen delivery systems for protection againstLeishmania donovani. J Control Release2010; 141: 199–207.
46.
RavindranRBhowmickSDasAet al. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol2010; 10: 181.
47.
ThakurAKaurHKaurS. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice. Immunobiology2015; 220: 1031–1038.
48.
BhowmickSAliN. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PloS One2009; 4: e5820.
49.
FirouzmandHBadieeAKhamesipourAet al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Trop2013; 128: 528–535.
50.
ChavoshianOBiariNBadieeAet al. Sphingomyelin liposomes containing soluble Leishmania major antigens induced strong Th2 immune response in BALB/c mice. Iran J Basic Med Sci2013; 16: 965–972.
51.
BadieeAKhamesipourASamieiAet al. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol2012; 132: 403–409.
52.
BadieeAJaafariMRSamieiAet al. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol2008; 15: 668–674.
53.
SharghVHJaafariMRKhamesipourAet al. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine2012; 30: 3957–3964.
54.
JaafariMRBadieeAKhamesipourAet al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine2007; 25: 6107–6117.
55.
MazumderSRavindranRBanerjeeAet al. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine2007; 25: 8771–8781.
56.
SharghVHJaafariMRKhamesipourAet al. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. Parasitol Res2012; 111: 105–114.
57.
RavindranRMajiMAliN. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid–trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol Pharm2011; 9: 59–70.
58.
MazumderSMajiMAliN. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Negl Trop Dis2011; 5: e1429.
59.
SohrabiYJaafariMRMohammadiAet al. Evaluation of immune response against leishmaniasis in resistance C57 BL/6 mice immunized with liposomes containing autoclaved Leishmania major with BCG. Cell Mol Biol Lett2005; 10: S98.
60.
ShimizuYYamakamiKGomiTet al. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorganic Med Chem2003; 11: 1191–1195.
61.
EskandariFTaleshGAParooieMet al. Immunoliposomes containing soluble leishmania antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis. Exp Parasitol2014; 146: 78–86.
62.
Tandrup SchmidtSFogedCSmith KorsholmKet al. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics2016; 8: pii: E7.
63.
KerstenGFCrommelinDJ. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta (BBA)1995; 1241: 117–138.
64.
DavisDGregoriadisG. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics. Immunology1987; 61: 229–234.
65.
GregoriadisGPanagiotidiC. Immunoadjuvant action of liposomes: comparison with other adjuvants. Immunology Lett1989; 20: 237–240.
66.
RussellDGAlexanderJ. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol1988; 140: 1274–1279.
67.
McConvilleMJBacicAMitchellGFet al. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci USA1987; 84: 8941–8945.
68.
NakanishiTHayashiAKunisawaJet al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol2000; 30: 1740–1747.
69.
BenneNvan DuijnJKuiperJet al. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines. J Control Release2016; 234: 124–134.
70.
BachmannMFJenningsGT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol2010; 10: 787–796.
71.
CarstensMGCampsMGHenriksen-LaceyMet al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine2011; 29: 4761–4770.
72.
OussorenCZuidemaJCrommelinDet al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.: II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta1997; 1328: 261–272.
73.
McLennanDNPorterCJCharmanSA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol2005; 2: 89–96.
74.
SinghMChakrapaniAO’HaganD. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines2007; 6: 797–808.
75.
HejaziHTasbihiMJaafariMet al. The role of liposomal CpG ODN on the course of L. major infection in BALB/C mice. Iran J Parasitol2010; 5: 47–54.
76.
BadieeADaviesNMcDonaldKet al. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine2007; 25: 4757–4766.
77.
WhiteKLRadesTFurneauxRHet al. Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells. J Pharm Pharmacol2006; 58: 729–737.
78.
GieselerRKMarquitanGHahnMJet al. DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: implications for HIV disease. Scand J Immunol2004; 59: 415–424.
79.
MacriCDumontCJohnstonAPRet al. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin Trans Immunol2016; 5: e66.
80.
LehmannCHKHegerLHeidkampGFet al. Direct delivery of antigens to dendritic cells via antibodies specific for endocytic receptors as a promising strategy for future therapies. Vaccines2016; 4: 8.
81.
SehgalKRaghebRFahmyTMet al. Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk. J Immunol2014; 193: 2297–2305.
82.
SaburAAsadMAliN. Lipid based delivery and immuno-stimulatory systems: master tools to combat leishmaniasis. Cell Immunol2016; 309: 55–60.
Perrin-CoconLAgaugueSCoutantFet al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine2006; 24: 1254–1263.
